Frost & Sullivan Laurels for MagForce Nanotechnologies' Breakthrough Nano-Based Cancer Therapeutic

LONDON--(BUSINESS WIRE)--June 14, 2005--Frost & Sullivan's 2005 Technology Innovation Award for the European nanotechnology industry is presented to MagForce Nanotechnologies. The award comes in recognition of the German company's development of a path-breaking nano-based cancer therapy that enables the precise targeting of cancer cells in almost any part in the body with millimetre precision.

"Its outstanding level of innovation in the field of nano-based cancer therapeutics, as exemplified by the development of novel nanosolutions such as the MFH(R) 300F system makes MagForce Nanotechnologies a true technology leader," notes Mr. Girish Solanki, Manager in the technology research division of Frost & Sullivan.

“The system shows exceptional power absorption and can be readily integrated into conventional clinically routine cancer treatment options”

In addition to pioneering nanosolutions for cancer therapy, MagForce Nanotechnologies also develops innovative tumour-specific therapeutics. The company has completed several studies in the field of cancer and tumour therapies and its products are undergoing clinical trials. While its main product -- the MFH(R) 300F -- is likely to be commercialised by 2007, MagForce has already developed two innovative technologies for glioblastoma (an aggressive form of brain tumour) and prostate carcinoma.

Irrespective of its location in the body, tumours are excited with nanoparticles by the MFH(R) 300F system. Depending on the tumour's location, nanoparticles can be introduced using methods such as interventional radiology or the stereotactic navigation-based injection (in brain tumours).

MagForce's patented absorption technology enables tumour cells to absorb these nanoparticles selectively. The nanoparticles, in turn support the selective heating of the tumour tissue on a cellular level, thereby destroying the tumour cells. Among the most significant features of this technology therefore, is the differential uptake of nanoparticles in tumour cells versus normal cells.

The MFH(R) 300F system allows physicians to select the target temperature for the tumour and the nanoparticles can then be administered in conjunction with conventional chemotherapy techniques or in thermoablation modes for the destruction of tumour cells.

"The system shows exceptional power absorption and can be readily integrated into conventional clinically routine cancer treatment options," adds Mr. Solanki. "Furthermore, using this system requires minimal training and invasive monitoring -- even physicians without specialist training can manoeuvre it."

About Frost & Sullivan

Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics and demographics. For more information, visit

Frost & Sullivan Awards are presented to companies that demonstrate best practices in their industry, commending the diligence, commitment, and innovative business strategies required to advance in the global marketplace. Frost & Sullivan rigorously analyses specific criteria to determine award recipients in a broad spectrum of market industries and landscapes. For more information, visit


Frost & Sullivan
Corporate Communications
Magdalena Oberland, +44 (0) 20 7915 7876

Better Be Business Wired.

Business Wire is the leading source for press releases, photos, multimedia and regulatory filings from companies and groups throughout the world.